1. Home
  2. RAVE vs NRSN Comparison

RAVE vs NRSN Comparison

Compare RAVE & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rave Restaurant Group Inc.

RAVE

Rave Restaurant Group Inc.

HOLD

Current Price

$2.45

Market Cap

35.4M

ML Signal

HOLD

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.79

Market Cap

28.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAVE
NRSN
Founded
1958
2017
Country
United States
Israel
Employees
N/A
15
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.4M
28.4M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
RAVE
NRSN
Price
$2.45
$0.79
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
23.9K
153.2K
Earning Date
05-07-2026
03-20-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
0.09
N/A
Revenue
$15,120,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$27.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.01
$0.68
52 Week High
$3.75
$2.60

Technical Indicators

Market Signals
Indicator
RAVE
NRSN
Relative Strength Index (RSI) 25.47 39.05
Support Level N/A $0.68
Resistance Level $3.49 $1.30
Average True Range (ATR) 0.14 0.07
MACD -0.02 -0.01
Stochastic Oscillator 2.00 11.94

Price Performance

Historical Comparison
RAVE
NRSN

About RAVE Rave Restaurant Group Inc.

Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: